Sanofi (SNY) Reports Isatuximab Phase 3 Trial Meets Primary Endpoint of Prolonging Progression Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Tweet Send to a Friend
Sanofi (NYSE: SNY) announces that the pivotal Phase 3 trial of isatuximab in patients with relapsed/refractory multiple myeloma met the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
